### Thursday, June 15, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:45</td>
<td><em>Keynote lecture: J. Edmond Charlton Lecture</em></td>
<td>K2 - 620</td>
</tr>
<tr>
<td></td>
<td>Individualized pain therapy based on phenotyping: are we there yet? Ralf Baron, Germany</td>
<td>K1 - 290</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Coffee Break in Exhibition Area</td>
<td>J1 - 144</td>
</tr>
</tbody>
</table>
| 15:00-16:30 | **Workshop 1:** Chair: Andrew Rice, UK Preparing for the advent of precision medicine for neuropathic pain: profiling and stratification methods in pre-clinical and clinical research  
Aligning preclinical research methods with the precision medicine agenda  
Patient stratification by symptom and sensory profiling in clinical trials  
Nanna Finnerup, Denmark  
Patient stratification by endogenous pain modulation measures in clinical trials  
David Yarnitsky, Israel  
Andrew Rice, UK  
Neuroplasticity: Miles to go before you sleep  
Andrew Rice, UK  
Concepts of pain management in clinical trials  
Lene Vase Toft, Denmark  
**Workshop 2:** Chair: Theodore Price, USA The pain biography: what early life injury and hyperalgesic priming teaches us about how pain becomes chronic  
Descending dopaminergic circuits and O2 dopamine neurons in the transition to chronic pain  
Theodore Price, USA  
Dorsal horn circuits mediating mechanical allodynia and the transition to a chronic pain state  
Rebecca Seal, USA  
Priming of spinal nociceptive processing/circuitry by neonatal injury  
Simon Beggs, UK  
**Workshop 3:** Chair: Lone Vase Toft, Denmark The contribution of the placebo response in pharmacological, physical- and surgical interventions: state of art, prediction and ethical considerations  
Discussion of how the placebo response may influence the outcome of clinical trials  
Lone Vase Toft, Denmark  
Recent advances in psychological and genetic prediction of the placebo response in clinical trials  
Rebecca Seal, USA  
Ethical and practical considerations for and against placebo control in the assessment of the effectiveness of physical and surgical analgesic interventions  
Andrew Rice, UK  
**Workshop 4:** Chair: Troels Jensen Staehelin, Denmark Testing sodium channel function in neuropathic pain  
Can peripheral and central effects of sodium channels be tested in neuropathic pain?  
Troels Jensen Staehelin, Denmark  
Heat- and cold-resistant action potentials in nociceptors  
Katharina Zimmerman, Germany  
Pharmacological evidence of sodium channel targeted interventions  
Simon Haroutounian, USA  
**Workshop 5:** Chair: Nurcan Üçeyler, Germany miRNAs involved in the pathogenesis of neuronal malfunction following nerve injury  
Nurcan Üçeyler, Germany  
mRNA containing exosomes for neuroimmune communication in the nervous system  
Marcia Mucangia, UK  
miRNS associated with human CRPS and mouse models of neuropathic pain  
Alexander Huettenhofer, Austria  
<p>| 16:45-17:30 | Opening Ceremony                                                                      | J1 - 144 |
| 17:30-19:30 | Networking Reception                                                                  | J1 - 144 |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 07:30-09:00 | Plenary Session II  
Chair: TBA  
Global Burden of Disease - The impact of neuropathic pain  
Fiona Blyth, Australia  
Clinical assessment of neuropathic pain  
Roy Freeman, USA |
| 09:00-10:00 | Workshop 6:  
Conditioned pain modulation: lessons learned, unanswered questions, future directions  
Chair: Serge Marchand, Canada  
CPM: clinical relevance and unanswered questions  
Serge Marchand, Canada  
Exploring individual variability in the experience of pain; what we've learned from fMRI studies  
Katja Wiech, UK  
Technical parameters of CPM methodology; important considerations for improving reliability and reporting  
Donna Kennedy, UK |
| 10:00-10:30 | Workshop 7:  
How to assess patients with neuropathic pain. facts and fallacies of quantitative sensory testing, neurophysiological techniques and skin biopsy  
Chair: Andrea Truini, Italy  
Neurophysiological techniques for dissecting neuropathic pain  
Andrea Truini, Italy  
Neuropathic pain: is quantitative sensory testing helpful?  
Elena Enax-Krumova, Germany  
Skin biopsy features in chronic pain conditions  
Nurcan Uşýýler, Germany |
| 10:30-12:00 | Workshop 8:  
Pre-clinical models of neuropathic pain: what can and can't they tell us, and what should we do about it?  
Chair: Andrew Rice, UK  
General overview: basing clinical practice and research on findings derived from pre-clinical models  
Blair Smith, UK  
Clinical relevance of existing animal models for neuropathic pain, their strengths and weaknesses and topics for improvement  
Andrew Rice, UK  
Existing neuro-imaging models for neuropathic pain, their clinical relevance, strengths and weaknesses and how we might improve them  
Karen Davis, Canada |
| 12:00-12:30 | Workshop 9:  
Chronic neuropathic pain in immune-mediated neurological diseases  
Chair: Aki Hietaharju, Finland  
Chronic neuropathic pain in immune-mediated peripheral neuropathies  
Aki Hietaharju, Finland  
Chronic neuropathic pain in multiple sclerosis  
Flemming Bach, Denmark  
Generation of neuropathic pain in immunological disorders  
Jacqueline Palace, UK |
| 12:30-14:00 | Workshop 10:  
Advances in Spinal Cord Stimulation: Insights on Potential Mechanisms  
Chair: TBA  
Status of Clini and SCS  
Stephen McMahon, UK  
Spinal modulatory mechanisms of SCS in experimental models of neuropathic pain  
Srinivas Raja, USA  
SFM and Experimental SCS  
Bert Joosten, The Netherlands |
| 14:00-15:00 | Workshop 11:  
Emerging cell-based therapy for neuropathic pain  
Chair: Jianguo Cheng, USA  
Mesenchymal stem cells prevent and reverse opioid tolerance and opioid-induced hyperalgesia  
Jianguo Cheng, USA  
Transplantation of cortical GABAergic precursor neurons to treat neuropathic pain and itch  
Allan Baumann, USA  
Bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion  
Ru-Rong Ji, USA |
| 15:30-17:00 | Workshop 12:  
Molecule to man approaches to investigate pathophysiological mechanisms and treatment of neuropathic pain  
Chair: Sukayman Dib-Hajj, USA  
Painful and painless sodium channelopathies and strategies for personalized treatment  
Sukayman Dib-Hajj, USA  
Developing cellular models of human pain channelopathies  
David Bennett, UK  
Genetic approach to painful peripheral neuropathies  
Catharina Faber, The Netherlands |
| 17:00-17:30 | Workshop 13:  
Back pain revisited: new insights for research, diagnosis and therapy  
Chair: Didier Bouchaïssa, France  
Subgrouping of back pain patients: where do we stand and where do we go?  
Didier Bouchaïssa, France  
New diagnostic tools on the rise: what are they good for?  
Philip Hüllmann, Germany  
Classical and emerging pharmacological treatments for low back pain: where do we stand?  
John Markman, USA |
| 17:30-19:00 | Workshop 14:  
How can we accelerate clinical advances from neuropathic pain research? Ideas from The Lancet’s "Research: Increasing Value, Reducing Waste" Initiative  
Chair: Gerd Antes, Germany  
An overview of the Lancet’s "Research: Increasing Value, Reducing Waste" initiative  
Gerd Antes, Germany  
Waste in pre-clinical neuroscience research with a focus on neuropathic pain  
Malcolm Mackird, UK  
Waste in neuropathic pain clinical trials: threats and opportunities  
Ian Gilron, Canada |
| 07:30-09:00 | Coffee Break, Poster Viewing, Visit Exhibition |
| 10:00-10:30 | Coffee Break, Poster Viewing, Visit Exhibition |
| 12:00-12:30 | Break and Visit Exhibition |
| 14:00-15:00 | Poster Discussion Session 1 |
| 15:30-17:00 | Industry Supported Symposia |
| 17:00-17:30 | Coffee Break, Poster Viewing,Visit Exhibition |
### Saturday, June 17, 2017

**Plenary Session IV**  
**Chair:** TBA  
**Neuropathic Itch**  
Sarah Ross, USA  
A Burning Mouth Syndrome is a Neuropathic Pain Condition?  
Satu Jääskeläinen, Finland  
Lene Baad-Hansen, Denmark

**Workshop 15:**  
**G1 - 175**  
**Plenary Session V**  
**K1 - 290**  
**Plenary Session IV**  
**K3 - 290**  
**Debate:**  
**Poster Session**  
**J1 - 144**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-09:00</td>
<td>Coffee Break, Poster Viewing, Visit Exhibition</td>
</tr>
</tbody>
</table>
| 09:00-10:00 | Plenary Session IV  
**Chair:** TBA  
**Neuropathic Itch**  
Sarah Ross, USA  
A Burning Mouth Syndrome is a Neuropathic Pain Condition?  
Satu Jääskeläinen, Finland  
Lene Baad-Hansen, Denmark |
| 10:00-10:30 | Coffee Break and Visit Exhibition                                     |
| 10:30-12:00 | Workshop 13:  
Recent advances in diagnosis and management of painful post-traumatic trigeminal neuropathy  
Chair: Barry Sessle, Canada  
The role of non-neural as well as neural elements, chemical mediators and genetic factors in trigeminal neuropathic pain  
Barry Sessle, Canada  
New insights into tests of orofacial somatosensory function  
Donna Kennedy, UK  
I can’t have carpal tunnel syndrome, it doesn’t hurt!  
Jeremy Bland, UK  
Peter Svensson, Denmark  
| 11:00-12:00 | Workshop 14:  
Entrapment neuropathies: challenging common beliefs with novel evidence  
Chair: Anonna Schmid, UK  
The pathophysiology of entrapment neuropathies: from bench to bedside  
Anonna Schmid, UK  
Does somatosensory phenotype predict the outcome of carpal tunnel surgery?  
Donna Kennedy, UK  
| 12:00-12:30 | Break and Visit Exhibition                                            |
| 12:30-14:00 | Plenary Session V  
**Chair:** TBA  
**Application of Optigenetics and Neuropathic Pain**  
Robert Gereau, USA  
How can genetic studies help our understanding on neuropathic pain?  
Ludia Datchenko, Canada |
| 14:00-15:00 | Workshop 16:  
**Entrapment neuropathies: challenging common beliefs with novel evidence**  
Chair: Anonna Schmid, UK  
The pathophysiology of entrapment neuropathies: from bench to bedside  
Anonna Schmid, UK  
Does somatosensory phenotype predict the outcome of carpal tunnel surgery?  
Donna Kennedy, UK  
| 15:00-16:00 | Workshop 17:  
Neuropathic pain regulation by astrocytes, microglia, and macrophages: pre-clinical and clinical evidence  
Chair: Ru-Rong Ji, USA  
Distinct roles of microglia and astrocytes in neuropathic pain  
Ru-Rong Ji, USA  
Distinct roles of microglia and macrophages in neuropathic pain  
Maria Malcangio, UK  
Imaging glial activation in patients with chronic pain  
Marco Loggia, USA  
| 16:00-17:00 | Workshop 18:  
Recent advances in the pharmacotherapy of neuropathic pain: focus on botulinum toxin  
Chair: Nadine Attal, France  
Botulinum toxin A type A: new data in peripheral neuropathic pain  
Nadine Attal, France  
Mechanisms of action of botulinum toxin in peripheral neuropathic pain  
Badrak Davletov, UK  
Perineural injections of botulinum toxin in neuropathic pain  
Christian Maier, Germany  
| 17:00-18:00 | Coffee Break and Visit Exhibition                                     |
| 18:00-19:00 | Debate  
**Determining small fibre rarefaction is skin punch biopsy indispensable?**  
Chair: TBA  
GSM to identify nerve fibre and Langerhans cell pathology  
Rayna Malik, Qatar  
Skin biopsy as a gold standard for assessing the ENMO  
Giuseppe Laursi, Italy  
| 19:00-20:00 | Workshop 19:  
Genetic and epigenetic regulation of neuropathic pain  
Chair: Greg Neely, Australia  
New high throughput models of neuropathic pain  
Greg Neely, Australia  
Genomic and transcriptomic profiling of neuropathic pain  
Michael Contigan, USA  
Epigenetics and pain what do we actually know  
Franceska Dank, UK  
| 20:00-21:00 | Workshop 20:  
**Tactile afferents in neuropathic pain**  
Chair: TBA  
C-tactile afferent inputs dynamic conversion between pleasure and pain  
Paul Ramprhar-Smith, UK  
Clinical aspects of CIPN: trials, treatment, and translation  
Lesley Cohen, UK  
Oxidative stress and cellular bienergetics in chemotherapy-induced neuropathies  
Sarah Flatters, UK  
| 21:00-22:00 | Workshop 21:  
British Journal of Anaesthesia Sponsored  
**Genomic and transcriptomic profiling of neuropathic pain**  
Chair: Greg Neely, Australia  
Clinical aspects of CIPN: trials, treatment, and translation  
Lesley Cohen, UK  
Oxidative stress and cellular bienergetics in chemotherapy-induced neuropathies  
Sarah Flatters, UK  
| 22:00-23:00 | Workshop 22:  
**C-tactile afferents in neuropathic pain**  
Chair: TBA  
C-tactile afferents in neuropathic pain: from molecular to clinical insights  
Chair: Hakan Olausson, Sweden  
Mechanisms of spontaneous activity induced by chemotherapy drugs in dorsal root ganglion neurons  
Patrick Dougherty, USA  
Clinical aspects of CIPN: trials, treatment, and translation  
Lesley Cohen, UK  
Oxidative stress and cellular bienergetics in chemotherapy-induced neuropathies  
Sarah Flatters, UK  
| 23:00-00:00 | Workshop 23:  
A multidisciplinary approach for stratifying patients with peripheral neuropathic pain  
Chair: Andreas Themistocleous, UK  
The Pain in Neuropathy Study: deep phenotyping to explore differences between painful and painless diabetic neuropathy  
Andreas Themistocleous, UK  
Patient autoncibodies against CASPR2 cause pain hypersensitivity in mice via the regulation of VGKC function in sensory neurons  
John Dawes, UK  
Altered potassium channel distribution and composition in myelinated axons suppresses hypersensitivity following injury  
Margarita Calvo, Chile  
Role of slow inactivating potassium current (IKQ) in cold transduction and cold allodynia  
Rodolfo Madrid, Chile  
|
## Sunday, June 18, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08:00-09:30| Workshop 24: Immunological mechanisms supporting CRPS: basic, translational and clinical evidence  
Chair: David Clark, USA  
Sensory and cognitive processing and the risk of PPSP  
IgM pronociceptive effects in CRPS  
David Clark, USA  
Immunoglobulin G mediated non-inflammatory autoimmunity in longstanding CRPS  
Andreas Goebel, UK  
Immunoglobulin G mediated non-inflammatory autoimmunity in longstanding CRPS: Translational evidence  
David Anderson, UK  
Basic, translational and clinical evidence for innate immune mediators in CRPS  
Tanja Schlereth, Germany |
| 09:30-10:00| Best Poster Session                                                  |
| 10:00-11:00| Plenary Session VI  
Chair/TBA  
Inflammation in the pathophysiology of neuropathic pain  
Claudia Sommer, Germany  
Debate: Adequacy of diagnostic tools for complex regional pain syndrome  
Christoph Maier, Germany  
Stephen Bruch, USA |
| 11:00-12:00| Workshop 25: Evoked potentials for diagnosing small fiber disease: cool or outdated?  
Chair: Philipp Hüllmann, Germany  
Cold evoked potentials - ready for clinical use?  
Philipp Hüllmann, Germany  
Persistent post-surgical pain (PPSP): Epidemiology, characteristics and current challenges  
Simon Haroutounian, USA  
Laser evoked potentials (LEPs) – the “gold standard”  
Andrea Truini, Italy  
Predictive biopsychosocial phenotypes associated with PPSP, and development of a risk algorithm for clinical decision-making  
Robert Edwards, USA  
Why should we combine contact heat (CHEPS) and pinprick evoked potentials (PEPs)?  
Ulf Baumgärtner, Germany  
Sirius evoked potentials (LEPs) – the “gold standard”  
Andrea Truini, Italy  
Evidence for dichotomous central noradrenergic organisation and its relevance for pain control  
Anthony Pickering, UK |
| 12:00-13:00| Workshop 26: Optogenetic and chemogenetic dissection of central noradrenergic control: relevance to neuropathic pain and its comorbidities  
Chair: Anthony Pickering, UK  
Evidence for dichotomous central noradrenergic organisation and its relevance for pain control  
Anthony Pickering, UK  
How the Locus Coeruleus influences the affective consequences of chronic pain  
Esther Barrocoso, Spain  
Dissecting locus coeruleus and amygdala circuit interactions in negative affect and pain  
Michael Bruch, USA |
| 12:00-13:00| Workshop 27: Improving the quality of pain trials  
Chair: Janne Gierthmühlen, Germany  
Who is healthy? Aspects to consider when including healthy volunteers  
Janne Gierthmühlen, Germany  
Research design considerations for chronic pain clinical trials  
Jennifer Gewandter, USA  
Considerations for outcome parameters in clinical pain trials: Is pain assessment a sufficient outcome parameter?  
Peter Tugwell, Canada |
| 12:00-13:00| Workshop 28: Research design considerations for chronic pain clinical trials  
Chair: Anthony Pickering, UK  
Evidence for dichotomous central noradrenergic organisation and its relevance for pain control  
Anthony Pickering, UK  
How the Locus Coeruleus influences the affective consequences of chronic pain  
Esther Barrocoso, Spain  
Dissecting locus coeruleus and amygdala circuit interactions in negative affect and pain  
Michael Bruch, USA |

### Legend
- **Plenary**
- **Workshop**
- **Poster Session**
- **Social Event**
- **Debate**

### Schedule
- **K2 - 620**
- **K1 - 290**
- **K3 - 290**
- **G1 - 175**
- **J1 - 144**